Get the Daily Brief
Latest Biotech News
Big Pharma M&A: Angelini’s U.S. rare-neurology push
Angelini Pharma agreed to buy Catalyst Pharmaceuticals in a cash deal valued at about $4.1 billion, adding three FDA-approved rare neurological medicines and a U.S. commercial platform. The offer...
Ophthalmology M&A: Bayer buys implant drugmaker Perfuse
Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, starting with a $300 million upfront payment, to expand its ophthalmology pipeline. Perfuse’s lead program, PER-001, is a...
Rare cancer regulators: FDA reconsiders Atara and Pierre Fabre’s Ebvallo
Atara Biotherapeutics and Pierre Fabre said FDA agreed to reconsider approval of Ebvallo after a surprise rejection earlier this year, following a late-April meeting. The companies said FDA’s...
Clinical data disappointment: Entrada’s Duchenne program stumbles
Entrada Therapeutics’ next-generation Duchenne muscular dystrophy drug disappointed in an early readout, sending the stock sharply lower and raising questions about the company’s competitiveness...
Precision oncology diagnostics: BillionToOne Unity Confirm and Q1 rebound
BillionToOne reported a major Q1 revenue jump, driven by higher prenatal clinical testing volume and a push to expand utilization of its Unity Aneuploidy screening offering through the newly...
Precision medicine AI finance: Tempus convertible notes offering
Tempus AI announced plans to raise $350 million through a convertible senior notes offering in a private placement, with net proceeds intended primarily to refinance debt. The company said it...
Oncology immunology deal: UCB buys Candid to grow T-cell engager portfolio
UCB agreed to acquire Candid Therapeutics for up to $2.2 billion, expanding its T-cell engager antibody pipeline for autoimmune and inflammatory indications. UCB said the deal adds Candid’s lead...
Diagnostics growth: Adaptive Biotechnologies raises MRD outlook
Adaptive Biotechnologies raised 2026 revenue guidance for its minimal residual disease business after strong Q1 growth in ClonoSeq-based testing. Adaptive now expects MRD revenue of $260...
Lab supply chain and biotech manufacturing: ChromaGenix spinout for viral vector purification
ChromaGenix, a spinout from North Carolina State University, launched a portfolio of peptide ligands designed to simplify viral vector purification for gene therapy manufacturing. The company is...
AI in diagnostics: Moonlight AI raises seed for imaging-to-biomarker platform
Moonlight AI raised $3.3 million to expand its diagnostic image-analysis software that links routine imaging—such as genomic biomarkers and disease signatures from blood and cytology smears—to...
Large pharma M&A reshapes ophthalmology pipelines
Bayer is set to expand its ophthalmology pipeline with its agreement to acquire Perfuse Therapeutics for up to $2.45 billion, the companies said. The deal gives Bayer rights to PER-001, a...
Second major deal boosts neurology rare-disease scale in the US
Angelini Pharma agreed to buy Catalyst Pharmaceuticals for roughly $4.1 billion in cash, a move that positions the Italian company to scale its rare-disease footprint and gain a more direct...
A new late-stage execution drive from a comeback MASH player
Madrigal extended its MASH growth strategy through a second licensing deal in the metabolic dysfunction-associated steatohepatitis space. The company licensed Arrowhead’s siRNA asset targeting...
Large oncology diagnostics growth: Tempus accelerates multimodal precision
Tempus reported a 36% year-over-year jump in Q1 revenue to $348.1 million and raised full-year guidance, reinforcing investor focus on its AI-driven diagnostics and data platform. The...
Biotech financing: Moonlight AI targets genomic biomarkers from routine imaging
Moonlight AI, a Swiss diagnostic image-analysis startup, raised $3.3 million in private financing as it advances software that identifies genomic biomarkers and disease signatures from routine...
New gene therapy commercialization milestone in South Korea
South Korea’s MFDS approved Curocell’s Rimqarto (anbalcabtagene autoleucel; anbal-cel) on April 29, marking the first homegrown CAR T-cell therapy approval for advanced diffuse large B-cell...
Clinical oncology: Phase 1/2 RAS inhibitor shows early signals in pancreatic cancer
Revolution Medicines’ daraxonrasib produced promising early anti-tumor effects in a Phase 1/2 trial in advanced pancreatic cancer, according to results published in the NEJM, with the study led by...
Rare-disease immunotherapy pipeline: Avalo’s IL-1β antibody advances after Phase 2 win
Avalo Therapeutics said its IL-1β-targeting antibody abdakibart met the primary endpoint in the Phase 2 Lotus trial in adults with moderate-to-severe hidradenitis suppurativa (HS). The company...
Precision oncology diagnostics: Blood test targets tumor microenvironment “neighborhoods”
Mayo Clinic and Stanford Medicine unveiled a blood test intended to map tumor “neighborhoods” via a noninvasive readout of the tumor microenvironment, aiming to predict immunotherapy response. The...
Biomarkers and MRD economics: Adaptive Biotechnologies lifts 2026 MRD guidance
Adaptive Biotechnologies raised its 2026 revenue guidance for its minimal residual disease (MRD) business after strong Q1 momentum in MRD testing volume. The Seattle-based company now expects...